SyncThink Releases Next Generation EYE-SYNC Concussion Solution
FDA-cleared eye tracking virtual reality device is comprehensive assessment for prominent clinic subtypes of concussion
Boston, MA—June 26, 2017—SyncThink, world leader in neuro-technology with foundational intellectual property in eye tracking metrics and devices, announces today the next generation of its FDA Cleared EYE-SYNC technology. EYE-SYNC is an objective and comprehensive assessment tool to assess ocular-motor synchronization, vestibular balance dysfunction, and is accompanied by the most recently released SCAT5. The EYE-SYNC now features a cloud-connected, HIPAA compliant analytics platform that delivers results in under 60 seconds without bias from the patient or clinician.
“Concussion is the most underreported, under diagnosed and underestimated type of brain trauma. There is no universally accepted, evidence-based definition of concussion and that’s the reason EYE-SYNC is so important to the health of athletes, soldiers, and patients alike,” said Ernest Santin, CEO of SyncThink. “Through over 10 years of clinical research, and obtaining 10 patents, our team at SyncThink has worked tirelessly to do our part to move brain health and performance into an objective space with the EYE-SYNC technology.”
EYE-SYNC is the first reliable tool to identify functional impairments in real time, enabling immediate remove-from-play decisions to be made. It provides the functionality to identify unresolved prior injury, the mobility to conduct a fast and objective assessment from the sidelines, as well as frequent monitoring to ensure recovery and predict return to play. Post-injury, the EYE-SYNC technology is a critical objective measure to monitor progress and provide confirmation that the impairment has resolved.
“The EYE-SYNC technology works as a method of surveillance, assessment, and recovery to reduce the risk of injury for those in all walks of life. There is no way to cheat this technology to convince medical professionals that you aren’t injured when you are, and that’s a giant step to making athletes safer,” said Dr. Jamshid Ghajar, Stanford University Clinical Professor of Neurosurgery, Chief Scientific Adviser and Founder of SyncThink. “We have to be able to access objective information to make clinical decisions regarding brain health and this next generation of EYE-SYNC delivers just that.”
As the only comprehensive concussion management solution, the EYE-SYNC technology allows for the migration and pushing of data across all platforms so that medical professionals can share secure information throughout the organization. Additionally, the platform provides several customizable options that can be integrated into pre-existing electronic medical records (EMR) and scaled accordingly.
Users of the first-generation EYE-SYNC technology will receive the updated solution, comprehensive training, and hands on support to ensure objective metrics become the forefront of the concussion management protocol.
SyncThink develops revolutionary eye-tracking technology products, now in VR headsets, that give medical professionals objective metrics for visual attention. Based on 15 years of research and holding over 10 patents, SyncThink’s first product, EYE-SYNC, is a 60-second, objective sideline assessment that uses eye tracking to evaluate for ocular-motor impairments and vestibular balance dysfunction – the two most common and serious components of concussion. FDA-cleared for detecting eye-tracking impairment, EYE-SYNC is used by leading university athletic departments and medical clinics, from Stanford University to Massachusetts General Hospital, EYE-SYNC is transforming concussion assessment, recovery, and monitoring. For more information or to contact SyncThink, please visit: www.syncthink.com.